Over 10,000 Potential Target

Section 1
Omics patient data from multiple sources: Responders vs. non-responders, active disease vs. remission
Input
Identify blind spots and linkages in immunometabolic pathways
80-100
TARGET PATHWAYS
In Silico
Use AI-based filter for druggability
Conduct multi-scale pathway modeling
(ODE & ABM)
5-10
TARGET PATHWAYS
In Silico
Leverage CRISPR, siRNA, shRNA experimental results with primary human and other cells
2-3
TARGET PATHWAYS
In Vivo
Characterize phenotype of knock-out mice and investigate effects in multiple animal models IBD, SLE MS, T1D